reports
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend SOUTHAMPTON, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the "Company"), the holding company for Quaint Oak Bank, announced today that its Board of Directors declared a quarterly cash dividend of $0.13 per share on the common stock of the Company on April 9, 2025. The dividend is payable on May 5, 2025, to the shareholders of record at the close of business on April 21, 2025. Quaint Oak Bancorp, Inc., a Financial Services Company, is the parent company for the Quaint Oak Family of Companies. Qua...
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Re...
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million as of December 31, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Feb. 27, 2025 (GLOBE N...
C4 Therapeutics to Participate in Upcoming March Investor Conferences
C4 Therapeutics to Participate in Upcoming March Investor Conferences WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in two upcoming March investor conferences. TD Cowen 45th Annual Healthcare Conference: Management will present on March 3rd at 9:10 am ET in Boston, MA. The live webcast will be available on the of the company’s website. The archived replay of the webcast will be avail...
QUAINT OAK BANCORP, INC. ANNOUNCES FOURTH QUARTER AND YEAR-END EARNING...
QUAINT OAK BANCORP, INC. ANNOUNCES FOURTH QUARTER AND YEAR-END EARNINGS Southampton, PA , Jan. 31, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (the “Company”) (OTCQB: QNTO), the holding company for Quaint Oak Bank (the “Bank”), announced today net income for the quarter ended December 31, 2024 of $1.6 million, or $0.60 per basic and diluted share, compared to net income of $1.1 million, or $0.49 per basic and diluted share, for the same period in 2023. Net income for the year ended December 31, 2024 was $2.8 million, or $1.08 per basic and diluted share, compared to net income of $2...
NYLI MacKay DefinedTerm Muni Opportunities Fund: 1 director
A director at NYLI MacKay DefinedTerm Muni Opportunities Fund bought 3,300 shares at 14.924USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend
Quaint Oak Bancorp, Inc. Declares Quarterly Cash Dividend SOUTHAMPTON, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (OTCQB: QNTO) (the "Company"), the holding company for Quaint Oak Bank, announced today that its Board of Directors declared a quarterly cash dividend of $0.13 per share on the common stock of the Company on January 15, 2025. The dividend is payable on February 10, 2025, to the shareholders of record at the close of business on January 27, 2025. Quaint Oak Bancorp, Inc., a Financial Services Company, is the parent company for the Quaint Oak Family of Comp...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols bymarket-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WHR WHIRLPOOL CORPORATION
SLAB SILICON LABORATORIES INC.
LAKE LAKELAND INDUSTRIES INC.
GTE GRAN TIERRA ENERGY
DXPE DXP ENTERPRISES INC.
COG CABOT OIL & GAS CORPORATION
AXGN AXOGEN INC.
ALLT ALLOT LTD
MEG. MEG ENERGY CORP.
PARR PAR PACIFIC HOLDINGS INC
VFC V.F. CORPORATION
CDZI CADIZ INC.
IRTC IRHYTHM TECHNOLOGIES INC.
DK DELEK US HOLDINGS INC
SWTX SPRINGWORKS THERAPEUTICS
PGNY PROGYNY
CRMD CORMEDIX INC.
LPI LAREDO PETROLEUM INC.
FNMA FEDERAL NATIONAL MORTGAGE ASSOCIATION
OVV OVINTIV INC
PTLO PORTILLOS INC
CIVI CIVITAS RESOURCES INC
ARHS ARHAUS INC
OPFI OPPFI INC
FTAI FORTRESS TRANSN & INFRAS INVS LLC
SN SHARKNINJA INC
ARPL ARLA PLAST AB
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of...
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma CFT1946 Phase 1 Trial Continues to Progress in BRAF V600X Solid Tumors With Monotherapy Dose Escalation Expected to Complete in 1H 2025; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 CFT8919 Progressing Through Phas...
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare C...
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that Andrew Hirsch, president and chief executive officer of C4T, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PST (5:15 pm EST). The presentation will be webcast live and may be accessed through C4T’s website on the . A replay...
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Soci...
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adv...
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter...
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Steve...
Sensient Technologies Corp: 1 director
A director at Sensient Technologies Corp sold 4,000 shares at 80.483USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- Jonathan Moreland
LOGI LOGITECH INTERNATIONAL S.A.
TCBI TEXAS CAPITAL BANCSHARES INC.
RRGB RED ROBIN GOURMET BURGERS INC.
PPSI PIONEER POWER SOLUTIONS
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
CROX CROCS INC.
AIN ALBANY INTERNATIONAL CORP. CLASS A
NSC NORFOLK SOUTHERN CORPORATION
ATLO AMES NATIONAL CORP.
TAYD TAYLOR DEVICES INC.
FBK FB FINANCIAL CORPORATION
CDZI CADIZ INC.
JELD JELD-WEN HOLDING INC.
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SNBR SLEEP NUMBER CORPORATION
ESQ ESQUIRE FINANCIAL HOLDINGS
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
MEC MAYVILLE ENGINEERING
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
TELA TELA BIO
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
BDSX BIODESIX
MODV MODIVCARE INC
UAN CVR PARTNERS LP
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
TRIN TRINITY CAPITAL INC
BGS B&G FOODS
NRDS INC.
MAIA NERDWALLET INC
SKYH MAIA BIOTECHNOLOGY INC
MBLY SKY HARBOUR GROUP CORP
NE MOBILEYE GLOBAL INC
CALC NOBLE CORP (NEW)
BYON CALCIMEDICA INC.
DRUG BEYON 3D LTD
IKT BRIGHT MINDS BIOSCIENCES INC
ARR INHIBIKASE THERAPEUTICS INC.
MIO ARMOUR RESIDENTIAL REIT INC.
OI PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
WPC OWENS ILLINOIS INC.
UMAC W. P. CAREY AND CO. LLC
EVM UNUSUAL MACHS INC NEV
PDYN EATON VANCE INSD CALIF MUN BD FD
SARCOS TECHNOLOGY AND ROBOTICS CORP
- Jonathan Moreland
INTC INTEL CORPORATION
HTLD HEARTLAND EXPRESS INC.
CDZI CADIZ INC.
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
BDSX BIODESIX
MODV MODIVCARE INC
TRIN TRINITY EXPLORATION & PRODUCTION
MBLY MOBILEYE GLOBAL INC
DRUG BRIGHT MINDS BIOSCIENCES INC
AMWL AMERICAN WELL CORP
OI OWENS ILLINOIS INC.
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Tria...
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial Clinical Development Initiated in Greater China by Partner Betta Pharmaceuticals WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally bioavailable allosteric degrader of EGFR L858R for non-small cell lung cancer (NSCLC), in Greater China. “We ...
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Ce...
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET) WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that two abstracts from the ongoing Phase 1/2 trial of cemsidomide have been accepted for presentation at the ASH Annual M...
QUAINT OAK BANCORP, INC. ANNOUNCES THIRD QUARTER EARNINGS
QUAINT OAK BANCORP, INC. ANNOUNCES THIRD QUARTER EARNINGS Southampton, PA , Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quaint Oak Bancorp, Inc. (the “Company”) (OTCQB: QNTO), the holding company for Quaint Oak Bank (the “Bank”), announced today net income for the quarter ended September 30, 2024 of $243,000, or $0.09 per basic and diluted share, compared to net loss of $255,000, or $(0.11) per basic and diluted share, net, for the same period in 2023. Net income for the nine months ended September 30, 2024 of $1.2 million, or $0.47 per basic and diluted share, net, compared to net income of $878,0...
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recen...
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA Initial Monotherapy CFT1946 Phase 1 Data Demonstrated Well-Tolerated Safety Profile and Early Evidence of Anti-tumor Activity; Phase 1/2 Trial Continues to Progress with Multiple Data Readouts Expected in 2025 Appointed Paige Mahaney, Ph.D. as Chief Scientific Officer Brin...
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5...
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 345,600 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the gra...
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.